Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.39 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8347704 | 0.84 | LMNA (0.46) | KDM4ENPC1LMNATP53CYP1A2 | |
| SCHEMBL5551094 | 0.83 | SIRT1 (0.46) | KDM4EMAPTALDH1A1PLA2G10PLA2G2A | |
| SCHEMBL8876740 | 0.83 | PLK1 (0.43) | KDM4ENPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6370206 | 0.82 | DGAT1 (0.49) | KDM4ENPC1LMNATP53CYP1A2 | |
| SCHEMBL6223649 | 0.81 | CYP4F2 (0.44) | PLA2G10PLA2G2AMKNK1MKNK2GPR52 | |
| SCHEMBL4632516 | 0.80 | ALDH1A1 (0.53) | KDM4ENPC1LMNATP53CYP1A2 | |
| SCHEMBL4638579 | 0.80 | SKP2 (0.57) | KDM4ENPC1LMNACYP1A2CYP3A4 | |
| SCHEMBL18676247 | 0.79 | SKP2 (0.56) | KDM4ENPC1LMNATP53CYP1A2 | |
| SCHEMBL23960204 | 0.79 | MKNK1 (0.44) | LMNAMAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6224042 | 0.79 | MKNK1 (0.44) | MKNK1MKNK2GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-6617347-B1 | Substituted pyrazoles are treatment of Type II diabetes and obesity. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-6265581-B1 | REACTING SPECIFIED EPOXIDE AND AMINE, REACTING PRODUCT WITH ACID TO FORM ACID ADDITION SALT | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-6093735-A | TREATMENT OF TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| US-6060492-A | SIDE EFFECT REDUCTION | ELI LILLY AND COMPANY (US) | 2000-05-09 | — | — | US | disclosed |
| US-6046227-A | USEFUL IN THE TREATMENT OF TYPE II DIABETES AND OBESITY; A SUBSTITUTED PYRAZINE COMPOUND | ELI LILLY AND COMPANY (US) | 2000-04-04 | — | — | US | disclosed |
| US-5977154-A | OBESITY, DIABETES | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | KDM4E 3200/4885NPC1 1881/4885LMNA 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.